Institutional investors are pushing for a range of reforms at publicly traded healthcare firms. High on the agenda is easier access to proxy ballots for an alternative slate of board directors.
Gilead Sciences' earnings tumbled more than 17% in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales.
Biologic drugmaker Gilead Sciences is buying a subsidiary of Nimbus Therapeutics and its experimental medicine for an increasingly prevalent metabolic disorder that causes dangerous fat buildup in the liver.
The federal jury in a high-stakes patent trial ordered drugmaker Gilead to pay rival Merck $200 million in damages for infringing on patents for hepatitis C drugs.
Everyone is in favor of value-based reimbursement in healthcare, right? If you're still wearing those rose-colored glasses, take a closer look at last week's reaction to Medicare's proposal to test new ways of paying for drugs administered in physician offices and hospital outpatient departments.
Members of the Senate's health committee voted Wednesday in favor of a bill that would add Zika to the list of 21 neglected, rare tropical diseases eligible for a voucher to fast-track approval by the FDA. Critics of the program say the FDA needs to prevent it from being exploited by drugmakers.
Gilead Sciences, the Foster City, Calif.-based drugmaker under pressure for its hepatitis C drug pricing, announced late last week that longtime CEO John Martin will step down from that role, becoming executive chairman of the company.
Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck.
Pennsylvania state officials Wednesday unveiled a $13 million, six-month program that will offer free hepatitis C antiviral medications for low-income individuals with a dual diagnosis of HIV and hepatitis C. According to the CDC, Pennsylvania had the 10th highest level of new HIV cases in the...
The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high.
High prescription drug prices will be a top-tier political issue in 2016 as the expected introduction of many expensive specialty medications to treat chronic conditions threatens to drive up healthcare spending.
Nearly seven-eighths of the country's top healthcare leaders favor the government taking a bigger role in curbing the rising cost of prescription drugs, while nearly all say that the two-year runup in drug prices has hurt their bottom lines.